GlaxoSmithKline debuts smaller, fast-dissolving Nicorette anti-smoking lozenge

GlaxoSmithKline launches mini Nicorette lozenges

NEW YORK — GlaxoSmithKline said Tuesday it is selling a fast-dissolving lozenge version of its Nicorette anti-smoking lozenges.

The British drugmaker said the new mini lozenge dissolves up to three times faster than similar products. It is designed to help relieve nicotine cravings and withdrawal symptoms, and comes in a small pocket-size vial. The company is launching the lozenges with a campaign that includes a Facebook contest.

GlaxoSmithKline reported about $529 million in nicotine replacement therapy revenue in 2009, including sales of Nicorette gum, Nicoderm CQ patches and Commit lozenges.

GlaxoSmithKline stock fell $1.12, or 2.9 percent, to close at $37.56.